secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-209789
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics Q1 revenue $22.5M, net loss $9.9M; Cullgen acquisition closed; NDA for F351 submitted
--------------------------------------------------------------------------------

- Q1 2026 revenue $22.5M (+2% YoY); GAAP basic EPS $(0.10); net loss $9.9M vs $3.7M net income YoY.
- Non-GAAP adjusted net loss $4.2M vs adjusted net income $2.9M in Q1 2025.
- Completed acquisition of Cullgen for ~$300M all-stock, expanding pipeline into inflammatory diseases and cancers.
- NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 with priority review.
- FY 2026 revenue guidance reaffirmed at $100.5-$111.0M; first patient enrolled in Phase 2/3 trial for radiation-induced lung injury.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/0001193125-26-209789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-209789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer